Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Constipation 6Intestinal Diseases 5Pain 3Neoplasms 2Opioid-Induced Constipation 1Cancer Pain 1

Interventions

Oxycodone 9Fentanyl 6Morphine 4resiniferatoxin 3nabiximols 3Naloxone 2Dronabinol 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1rofecoxib 1naloxegol 1fulranumab 1cannabichromene 1alvimopan 1Venlafaxine Hydrochloride 1Ultracet 1Tapentadol 1Standard of Care 1Radiation 1Propofol 1Nerve Growth Factor 1Methadone 1Memantine 1Inosine Monophosphate 1Hydromorphone 1Electroencephalography 1Duration of Therapy 1Cannabidiol 1Antibodies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cancer Pain × alvimopan × Clear all
NCT00101998 2017-08-30

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
233 enrolled
Other

Cancer Pain, Constipation, Intestinal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡